驱动力(838275) - 2022 Q3 - 季度财报

Financial Performance - Operating revenue for the first nine months of 2022 was approximately CNY 106.03 million, an increase of 8.68% year-on-year[15]. - Net profit attributable to shareholders decreased by 52.47% to approximately CNY 14.58 million[15]. - Basic earnings per share for the first nine months of 2022 were CNY 0.09, down 60.87% from the previous year[15]. - Revenue for Q3 2022 was approximately CNY 41.80 million, a 9.78% increase compared to Q3 2021[15]. - Net profit for Q3 2022 was approximately CNY 8.43 million, a decrease of 17.90% year-on-year[15]. - The net profit attributable to shareholders for the first nine months of 2022 was CNY 14.58 million, a decrease of 52.47% year-on-year, while the net profit after deducting non-recurring items was CNY 8.14 million, down 69.22%[18]. - The total profit for Q3 2022 was CNY 9,143,257.18, a decline of 24.5% compared to CNY 12,074,394.59 in Q3 2021[49]. - The company's gross profit margin for Q3 2022 was approximately 56.9%, compared to 62.3% in Q3 2021[52]. - The company's retained earnings decreased to ¥31,003,398.28 from ¥34,198,819.23, a decline of about 9.3%[45]. Assets and Liabilities - Total assets as of September 30, 2022, were approximately CNY 262.94 million, a decrease of 5.43% compared to the end of the previous year[15]. - The company reported a debt-to-asset ratio of 7.68% on a consolidated basis, up from 5.04% at the end of the previous year[15]. - The company's total assets as of September 30, 2022, amounted to CNY 262.23 million, a decrease of 5.43% year-on-year, primarily due to a reduction in cash and receivables[17]. - The total liabilities increased to CNY 19,937,426.00 from CNY 13,576,301.94, marking an increase of approximately 47.5%[40]. - The total assets of Guangdong Drive Biological Technology Group as of September 30, 2022, amounted to CNY 262,940,945.83, a decrease from CNY 277,276,529.02 at the end of 2021[38]. - The company's cash and cash equivalents were CNY 10,859,972.12, down from CNY 32,399,560.97 at the end of 2021, indicating a significant liquidity reduction[38]. - The accounts receivable decreased to CNY 33,044,155.03 from CNY 39,036,068.40, reflecting a decline of approximately 15.4%[38]. - The company's inventory decreased to ¥7,955,963.12 from ¥9,298,984.81, reflecting a reduction of about 14.4%[44]. Cash Flow - Cash flow from operating activities increased significantly by 7,762.57% to approximately CNY 36.52 million[15]. - The net cash flow from operating activities for the first nine months of 2022 was CNY 36,517,064.14, compared to CNY 464,441.59 in the same period of 2021, indicating a substantial improvement[56]. - Cash inflow from operating activities for the first nine months of 2022 was CNY 132,651,880.32, a significant increase from CNY 88,685,470.29 in the same period of 2021, marking a growth of approximately 49.6%[56]. - Cash outflow from investing activities for the first nine months of 2022 totaled CNY 261,578,579.41, compared to CNY 249,128,553.60 in 2021, reflecting an increase of about 5%[56]. - The net cash flow from investing activities for the first nine months of 2022 was -CNY 22,077,489.40, an improvement from -CNY 35,848,541.90 in the same period of 2021[56]. - Cash inflow from financing activities amounted to 56,226,400.00, with no new borrowings or bond issuances reported[60]. - Cash outflow for financing activities was 35,599,626.59, up from 20,786,002.39 in the previous period[60]. - The net increase in cash and cash equivalents was -21,072,265.77, compared to a slight increase of 378,653.20 previously[60]. Dividends and Shareholder Information - The company distributed cash dividends of CNY 34.11 million during the reporting period, impacting retained earnings[17]. - The proposed dividend distribution for the third quarter is CNY 0.80 per 10 shares, with no stock bonus or capital increase planned[35]. - The total number of ordinary shares at the end of the reporting period was 160,277,600 shares, with 5,054 shareholders[24]. - The stock option plan for 2022 involved granting 1,887,914 options to 32 individuals, with an exercise price set at CNY 4.61 per option[36]. Research and Development - The company is focused on developing new products and technologies in the feed additive sector to enhance nutritional value and improve animal health[6]. - The company is focusing on market expansion through the introduction of new products aimed at cost reduction and efficiency improvement for downstream industries[18]. - Research and development expenses for Q3 2022 were CNY 907,325.24, slightly down from CNY 948,143.14 in Q3 2021[52]. Other Financial Metrics - Non-recurring gains and losses totaled CNY 7.55 million for the reporting period, with a net amount of CNY 6.44 million after tax[21]. - The company’s weighted average return on equity was 3.47% for the reporting period, down from 4.04% in the previous year[19]. - The company incurred a credit impairment loss of CNY 1,553,916.12 in Q3 2022, compared to a loss of CNY 431,120.48 in Q3 2021[49]. - The company reported a significant increase in other income to ¥37,665.00 in Q3 2022 from ¥520,000.00 in Q3 2021, indicating a change in revenue sources[48]. - Basic and diluted earnings per share for Q3 2022 were both CNY 0.16, up from CNY 0.05 in Q3 2021, representing a 220% increase[53].